Guotong New Drug

Guotong New Drug (Suzhou) is a specialized biotechnology subsidiary of Grandpharma (China) Co., Ltd., focused on the research and development of innovative therapeutic and diagnostic agents. The company serves as a core R&D hub for Grandpharma's nuclear medicine and precision oncology portfolio, particularly emphasizing radionuclide-drug conjugates (RDCs). Guotong manages a robust pipeline of radiopharmaceuticals through strategic international collaborations with partners such as Telix Pharmaceuticals and ITM. Its lead programs include advanced treatments and imaging agents for neuroendocrine tumors, prostate cancer, and renal cell carcinoma. The company is headquartered in the Suzhou Industrial Park, a major biotech hub in China.